DM
Deerfield Management Portfolio holdings
AUM
$7.8B
1-Year Est. Return
76.63%
This Fund
S&P 500
1 Year Est. Return
+76.63%
AUM
$7.8B
AUM Growth
+$1.28B
(+20%)
Holding
184
Top Buys
| 1 | +$85.1M | |
| 2 | +$80.6M | |
| 3 | +$63M | |
| 4 |
Stoke Therapeutics
STOK
|
+$54.8M |
| 5 |
Lantheus
LNTH
|
+$48.2M |
Top Sells
| 1 | +$287M | |
| 2 | +$110M | |
| 3 | +$105M | |
| 4 |
Centene
CNC
|
+$97.3M |
| 5 |
Merck
MRK
|
+$86.4M |
Sector Composition
| 1 | Healthcare | 87.23% |
| 2 | Real Estate | 0.35% |
| 3 | Financials | 0.06% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Consumer Staples | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Certara
CERT
$1.12B
| $68.8M | 0.88% |
7,808,605
+1,069,068
|
|
||
27
Bio-Rad Laboratories Class A
BIO
$7.55B
| $68.5M | 0.88% |
226,070
|
|
||
28
Acadia Healthcare
ACHC
$2.12B
| $64.1M | 0.82% |
4,520,000
+3,331,000
|
|
||
|
BBOT
29
BridgeBio Oncology
BBOT
$806M
| $61.2M | 0.78% |
4,885,446
|
|
||
|
30
Stoke Therapeutics
STOK
$2.1B
| $57.9M | 0.74% |
+1,823,500
|
|
||
|
31
Lantheus
LNTH
$5.06B
| $55.1M | 0.71% |
+827,999
|
|
||
32
Structure Therapeutics
GPCR
$4.44B
| $53.4M | 0.68% |
767,993
+394,586
|
|
||
33
Envista
NVST
$4.82B
| $49.5M | 0.63% |
2,280,498
-13,538
|
|
||
34
Enhabit
EHAB
$687M
| $43.8M | 0.56% |
4,747,746
|
|
||
35
Kymera Therapeutics
KYMR
$7.21B
| $43.7M | 0.56% |
561,170
-11,088
|
|
||
36
CareDx
CDNA
$964M
| $41.3M | 0.53% |
2,191,000
|
|
||
37
Disc Medicine
IRON
$2.51B
| $40.6M | 0.52% |
511,163
-408,240
|
|
||
|
SION
38
Sionna Therapeutics
SION
$1.51B
| $39.9M | 0.51% |
970,590
|
|
||
|
BLTE
39
Belite Bio
BLTE
$6.66B
| $37.4M | 0.48% |
+233,813
|
|
||
40
Day One Biopharmaceuticals
DAWN
$1.06B
| $34.7M | 0.44% |
3,723,131
-982,282
|
|
||
41
Phreesia
PHR
$740M
| $33.8M | 0.43% |
1,999,045
+882,293
|
|
||
42
Embecta
EMBC
$592M
| $32.7M | 0.42% |
2,752,031
+131,610
|
|
||
43
Veracyte
VCYT
$2.85B
| $30.6M | 0.39% |
726,000
|
|
||
|
BBNX
44
Beta Bionics
BBNX
$556M
| $28.6M | 0.37% |
938,308
-230,107
|
|
||
45
Ventas
VTR
$41.2B
| $27.4M | 0.35% |
354,000
|
|
||
46
Alnylam Pharmaceuticals
ALNY
$43.1B
| $27M | 0.35% |
67,935
|
|
||
47
Tango Therapeutics
TNGX
$1.55B
| $25.8M | 0.33% |
+2,906,946
|
|
||
48
Xenon Pharmaceuticals
XENE
$3.29B
| $24.3M | 0.31% |
542,020
|
|
||
49
Spyre Therapeutics
SYRE
$3.34B
| $23.3M | 0.3% |
710,626
+96,961
|
|
||
50
Foghorn Therapeutics
FHTX
$337M
| $19.7M | 0.25% |
3,649,211
+393,697
|
|